Axonics (AXNX) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXNX shares.
View AXNX analyst ratings or view top-rated stocks.

11 analysts have issued 1 year target prices for Axonics' shares. Their AXNX share price forecasts range from $70.00 to $90.00. On average, they predict the company's stock price to reach $76.36 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.

Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX shares have decreased by 11.7% and is now trading at $55.20.
View the best growth stocks for 2023 here.

Axonics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,090,000 shares, an increase of 7.7% from the August 15th total of 2,870,000 shares. Based on an average daily volume of 697,500 shares, the days-to-cover ratio is currently 4.4 days.
View Axonics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our AXNX earnings forecast.

Axonics, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.03. The business had revenue of $92.90 million for the quarter, compared to analysts' expectations of $86.45 million. Axonics had a negative trailing twelve-month return on equity of 5.60% and a negative net margin of 10.06%. The company's revenue was up 34.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.47) earnings per share.

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares U.S. Medical Devices ETF (IHI).

Axonics issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million.

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Axonics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.46%), Bellevue Group AG (4.41%), Champlain Investment Partners LLC (3.45%), Credit Suisse AG (2.67%), State Street Corp (2.39%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends.

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXNX stock can currently be purchased for approximately $55.20.

Axonics (NASDAQ:AXNX) has a market capitalization of $2.79 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

The company employs 610 workers across the globe.

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.